J Nucl Med: Safety and dose assessment of the treatment of osteosarcoma with the radioactive drug 177DOTA-ZOL

It is well known that the use of radioactively labeled bisphosphonates for bone metastasis is a proven safe and effective palliative therapy.
177Lu-DOTA-Cyric acid (177Lu-DOTA-ZOL) is a new radioactive drug for bone metastasis.
this is a forward-looking study in which researchers evaluated the safety and dosage of 177DOTA-ZOL at a single therapeutic dose based on a range of SPECT/CT images and blood samples.
recruited nine patients with metastatic demotageable prostate cancer (mCRPC) with extensive bone metastasis progression under routine treatment (70.8±8.4 years).
patient underwent 3D full body SPECT/CT scans and intravenous blood transfusions within 7 days of receiving 5780±329MBq 177Lu-DOTA-ZOL.
dose assessment of major organs and tumor lesions was carried out.
are evaluated for safety through blood biomarkers.
in all patients, osteopathy rapidly ingests 177Lu-DOTA-ZOL and is highly trapped, while 177Lu-DOTA-ZOL is quickly removed from the bloodstream.
6 hours after injection, the average retention in tumor lesions was 0.02% IA/g, and 170 hours after injection, the average retention in tumor lesions was 0.01% IA/g.
in this group, the average absorption doses for bone tumor lesions, kidneys, red bone marrow and bone surface were 4.21, 0.17, 0.36 and 1.19 Gy/GBq, respectively.
bone marrow was found to be a dose-limiting organ for all patients.
the medium maximum resistance injection activity of 6.0 GBq may exceed the defined threshold of 2 Gy for red bone marrow per patient.
, 177Lu-DOTA-ZOL is safe to treat osteoblastoma and has a good therapeutic index compared to other radioactive drugs.
, individual dose determination should be considered to avoid severe blood toxicity in individual patients.